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Abstract
Objective: While most allergic responses to food are directed against protein epitopes and occur within 30
minutes of ingesting the allergen, recent studies suggest that delayed reactions may occur, sometimes mediated
by IgE antibodies directed against carbohydrate moieties. The objective of this review is to summarize the clinical
features and management of delayed hypersensitivity reactions to mammalian meat mediated by IgE antibodies to
galactose-alpha 1,3-galactose (alpha-gal), an oligosaccharide.
Methods: A PubMed search was conducted with MeSH terms: galactosyl-(1,3) galactose, oligosaccharides,
cetuximab, allergy/hypersensitivity, and anaphylaxis. Reported cases with alpha-gal-mediated reactions were
reviewed. This research study was approved by the Institutional Review Board of East Tennessee State University.
Results: Thirty-two cases of adults presenting with red-meat induced allergy thought to be related to
oligosaccharides have been reported in the literature so far, making this a rare and evolving syndrome. Most of
these patients demonstrated delayed reactions to beef, as was seen in the case reported by us in this manuscript.
IgE specific to alpha-gal was identified in most patients with variable response to skin testing with beef and pork.
Inhibition studies in some cases showed that the IgE antibodies to beef were directed towards alpha-gal in the
meat rather than the protein. The patients often reported history of tick bites, the significance of which is unclear
at present. Reactions to cetuximab, a monoclonal antibody, are mediated by a similar mechanism, with IgE
antibodies directed against an alpha-gal moiety incorporated in the drug structure.
Conclusion: Alpha-gal is an oligosaccharide recently incriminated in delayed anaphylactic reactions to mammalian
meats such as to beef, pork, and lamb. It appears that anaphylactic reactions to the anti-cancer biological agent,
cetuximab, may be linked mechanistically to the same process. More studies are required to understand the
underlying molecular basis for these delayed reactions in specific, and their broader implications for host defense
in general.
Keywords: Galactosyl-(1,3) galactose, Oligosaccharides, Cetuximab, Anaphylaxis, Food allergy, Delayed
hypersensitivity

Introduction
Beef Allergy and the New Evolving Syndrome

Food allergy remains a well-recognized problem that
affects people of different ages and can alter their quality of life [1,2]. Its prevalence and incidence seem to be
increasing over the past years [3-7] with more cases of
food-induced anaphylaxis being reported [8-11]. Food
hypersensitivity reactions are usually mediated by IgE
* Correspondence: saleh.hana@gmail.com
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antibodies against the incriminated food allergens such
as eggs, seafood, milk, tree nuts, peanuts, wheat, soy,
and rarely beef (Additional file 1: Table S1) [8,10-13].
The development of IgE-mediated reaction to a food
that was well tolerated in the past sometimes constitutes
a true diagnostic and therapeutic challenge to the
patient and the physician [14]. The prevalence of food
allergy has been increasing, with up to 4% of children
having allergic reactions to one or more foods, of which
reactions to peanut, soy, wheat, and seafood are probably most common [8,10-15]. While clinical tolerance to
food allergens occurs in many children, some such as
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peanut and shell fish are characterized by the tenacity of
the sensitization and persistence of sensitivity into adulthood [12,13,15-17].
Among food allergies, hypersensitivity to red meat is
less common [18-22]. It was not adequately studied
until recently, with a few reports emphasizing the probable cross reactivity between beef, cow’s milk, and other
types of red meat [23-31]. Some of the reactions,
referred to as “pork-cat syndrome”, involve cross-reactivity between cat epithelial allergens and pork [32-39].
The presentations of allergic reactions to meat, as
reported in the literature, are reviewed in Additional file
2: Table S2. These include allergic reactions to meat
protein, oral allergy syndrome (food-pollen syndrome),
the pork-cat syndrome as explained earlier, and some
forms of exercise-induced anaphylaxis [18-41].
It was assumed that reactions to mammalian meats
would be immediate, and due to IgE directed against specific protein allergens such as bovine serum albumin
(BSA) [22,27,42-46]. However, over the past few years
investigators have described a new syndrome characterized by delayed reactions to mammalian meat associated
with IgE antibodies directed against oligosaccharides
[14,47,48]. Chung et al. first reported on IgE antibodies
specific to galactose-alpha 1,3-galactose (alpha-gal), an
oligosaccharide present in non-primates [49,50], when
studying allergic reactions in cancer patients treated with
cetuximab [51]. Commins et al. later reported on the role
of oligosaccharides and IgE antibodies to alpha-gal in
allergy to red meat [14,47,48]. This article will review 31
cases of delayed beef reactions from around the world
[18,48,52,53], along with one case from our clinic. It
summarizes the current understanding of this rare, novel,
and evolving syndrome.
Historical Perspectives in the Discovery of Alpha-galmediated Allergy

Alpha-gal (Figure 1) is an oligosaccharide found in mammalian cells of non-primates [49,50]. The alpha-gal epitope is present in beef, pork, lamb [14,47-49], and cat
dander [54,55], but is absent in chicken and fish [49].
Beta-galactosyl alpha 1,3 galactosyl transferase, the enzyme
needed for formation of alpha-gal, is inactivated in
humans and higher mammals due to an evolutionary process. As a result, immunocompetent individuals may form
IgG isotype antibodies to alpha-gal [49,56]. These antibodies contribute to immediate rejection of xenotransplants
such as with “pig organs” in humans (recipients). At the
same time, the high immunogenicity of alpha-gal may
allow for the generation of anti-viral vaccines, as well as
tumor vaccines that also carry the alpha-gal epitope [49].
Exposure to food allergens (including perhaps alpha-gal
in mammalian meat) results in the generation of IgG
antibodies from B cells and hence development of
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immune tolerance. In predisposed individuals, due to
possible genetic/environmental factors (such as a fatty
diet, or tick bites), exposure of antigen presenting cells to
alpha-gal leads to Th2 activation and induction of interleukins, leading to IgE formation by B cells. This culminates in mast cell activation, eosinophilia, and the full
gamut of IgE-mediated hypersensitivity reactions characterized by urticaria, angioedema, and progression to systemic anaphylaxis in some patients [8,57,58].
Cetuximab; Introduction, Infusion reactions, and Link to
Meat Allergy

Cetuximab is a recombinant chimeric epidermal growth
factor monoclonal antibody approved for treatment of
metastatic colorectal and head and neck cancer
[51,59-61]. Initial studies on cetuximab started in 2000,
when IMC-C225, was shown to inhibit the growth of
pancreatic cancer cells [62]. Further studies and clinical
trials on this monoclonal antibody, later given the name
cetuximab, were conducted [63-66]. It was shown that
cetuximab binds to tumor cells, and is able to activate
natural killer cells, eosinophils, and neutrophils to target
them against these cancer cells [67]. In 2004, cetuximab
was approved for the treatment of colon cancer (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108244.htm) [59], and subsequently for
treatment of squamous cell head and neck cancer in
2006 (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108609.htm). Since 2002,
cetuximab has induced severe hypersensitivity reactions
[51,68-70] that have led physicians to further study the
nature of these reactions, and determine the appropriate
management [71-73]. In 2007 and 2008, reports showed
that the infusion reactions were more prevalent in Southeastern United States [51,68] (Figure 2A). This distribution is of interest, and may be related to other factors,
including diet as well as exposure to the Lone Star Tick
[74] (Figure 2B). In 2008, Chung et al. identified IgE antibodies to alpha-gal in patients who developed mild to
severe allergic reactions, including anaphylaxis, following
treatment with cetuximab [51]. Then, in 2009, Commins
et al. reported on a similar geographic distribution of
patients presenting with delayed allergic reaction to red
meat, and studies were able to detect IgE to alpha-gal in
these patients as well [48]. More patients with this interesting syndrome were further studied in Europe in 2009
and 2011 [18,52]. Figure 3 summarizes the chronological
events starting with the discovery of cetuximab, the allergic reactions reported, the role of alpha-gal in these reactions, and the link to red meat allergy.
The Cetuximab Hypersensitivity Syndrome

Reactions to biological agents (and most drugs) can be
classified as IgE and non-IgE mediated reactions, and
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Figure 1 Structure of galactose-alpha 1,3-galactose (alpha-gal). Alpha-gal is an oligosaccharide found in mammalian cells of non-primates
[49,50]. The alpha-gal epitope is present in beef, pork, lamb [14,47-49], and cat dander [54,55], and absent in chicken and fish [49]. Betagalactosyl alpha 1,3 galactosyl transferase, the enzyme needed for formation of alpha-gal, is inactivated in humans and higher mammals [49,56].

can present in the form of skin, pulmonary, or cardiac
manifestations [77-79]. Non-IgE reactions may be secondary to cytokine release and/or tumor lysis syndrome
[80-84]. In the case of cetuximab, evidence suggests that
these reactions are IgE mediated and represent true
anaphylaxis.
As mentioned earlier, Chung et al. identified IgE antibodies to alpha-gal in patients presenting with severe
infusion reactions to cetuximab [51]. In this series, the
authors reported on the presence of IgE antibodies
against cetuximab in sera from four groups of patients:
76 patients treated with cetuximab in the South-Eastern
United States, 72 healthy control subjects in Tennessee,
49 control subjects with cancer in California, 3 treated
with cetuximab, and 341 control subjects in Boston. The
authors show that 25/76 subjects treated with cetuximab
in Tennessee had clinical hypersensitivity to the drug,
and samples from 17 of those demonstrated IgE antibodies to cetuximab, compared to only 1/51 in those
patients who did not have a hypersensitivity reaction.
The IgE antibodies were also found in 15/72 control
subjects in Tennessee and only in 3/49 samples in
Northern California and 2/341 control samples from
Boston. The studies showed that these IgE antibodies
are directed against the alpha-gal component of the Fab
fragment of cetuximab heavy chain (Figure 4) [51,85]. A
recent study by van Bueren et al. [85] reported the presence of alpha-gal epitopes in the Fc portion of several
monoclonal antibodies including infliximab, basiliximab,
palivizumab, panitumumab, and cetuximab. However,
only cetuximab was found to contain alpha-gal in the
Fab region of the heavy chain, and interestingly, was the

only drug able to bind to IgE specific to alpha-gal (Figure 4) [85]. IgE to alpha-gal failed to bind to the Fc portion of the drugs due to several factors [85]. This might
explain the tolerance of some patients to panitumumab
after experiencing severe reactions to cetuximab [86-88].
Each cetuximab molecule contains two alpha-gal epitopes that can cross-link the high affinity receptor for
IgE (FcεRI) on mast cells [51]. IgE crosslinking of FcεRI
leads to activation of mast cells and degranulation with
release of hypersensitivity mediators including histamine, prostaglandins, leukotrienes, tryptase, and cytokines [57]. The possible mechanisms behind the
cetuximab reactions are demonstrated in cartoon format
in Figure 4.
Clinical Presentation and Diagnosis of Alpha-gal-related
Meat Allergy

The clinical presentation of alpha-gal-related red meat
allergy is similar to other food allergies, but has many
unique characteristics (Additional file 3: Table S3).
Upon presentation with suspected food allergy, history
taking remains the initial tool for diagnosis [12,18].
Patients with beef allergy related to alpha-gal have
symptoms that are common to other food induced
hypersensitivity reactions including urticaria, dyspnea,
hypotension, angioedema, or even full blown anaphylactic shock [18,48,52,53], but with the caveat that reactions occur hours after the ingestion of an incriminated
food. This sometimes makes the diagnosis difficult. A
detailed history including type of ingested foods, time to
onset of symptoms, the geographic area of residence as
well as history of tick bites, can help in achieving the
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Figure 2 Areas in USA where IgE to alpha-gal is common and the associated tick. A: Map of United States of America with highlights on
the south-eastern region in which reactions to cetuximab [51], as well as seropositivity to alpha-gal in delayed red meat allergy [48], are most
prevalent. B: Lone star tick (Amblyomma americanum), most prevalent in southeast USA and linked to alpha-gal allergy [74-76]. Image used with
permission from Iowa State University Entomology department; Credit to John VanDyk.
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Figure 3 The events in the understanding of cetuximab and Alpha-gal-mediated hypersensitivity. With the use of cetuximab in
treatment of head and neck cancer and colorectal carcinoma, multiple infusion reactions were reported. Chung el al. in 2008 were able to
identify IgE to alpha-gal directed to the Fab portion of cetuximab and was related to the allergic reactions. IgE to alpha-gal was later linked to
allergic reactions to red meat in America and Europe. Information from references: [18,51,52,59-74].

diagnosis. A patient presenting from the South-Eastern
United States with allergy to red meat occurring up to
3-7 hours after ingestion, and with a history of tick
bites, would be suggestive of alpha-gal allergy.
In general, confirming the diagnosis of a specific food
allergy has many components. Although food challenges
remain the “gold standard” for definitive diagnosis
[12,13], most physicians would start with basic tests
including skin prick test (SPT), intradermal testing, or

patch testing with the suspected allergen. In some cases
where skin tests could not be performed, serum IgE antibody quantification for the suspected allergen/s is safe
and easy [12], but there is high number of false positive
results, and the IgE level does not necessarily correlate
with the severity of the reaction [8,12]. The approach to
delayed food reactions however has some caveats. A food
challenge may be unnecessary if the history and serological tests are confirmatory, and may in fact be dangerous.
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Figure 4 The possible mechanism behind cetuximab induced allergies. Cetuximab is a recombinant chimeric epidermal growth factor
monoclonal antibody approved for treatment of metastatic colorectal and head and neck cancer [51,59-61]. Infusion reactions with cetuximab
are linked to the presence of IgE antibodies directed against the alpha-gal component of the Fab fragment of cetuximab heavy chain [51,85].
Each cetuximab molecule contains two alpha-gal epitopes that can cross-link the high affinity receptor for IgE (FcεRI) on mast cells [51] leading
to mast cell activation and release of hypersensitivity mediators [57].

Food challenges are best conducted in research environments and their role is yet to be defined in the delayed
reactions to mammalian meats.
In the USA, Commins et al. at University of Virginia
Health System are the leaders in studying delayed red

meat allergy [14,47,48]. They studied 24 patients with
IgE to alpha-gal [48]: 4 initially presented with hypersensitivity to beef, 15 identified from a cohort study of
243 patients, and 5 presenting from a clinic in Missouri.
All 24 patients had delayed allergic reactions after
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ingestion of red meat. Patients were between the ages of
18 and 80 years, 14 males and 10 females, and presenting from southeast United States. In addition to IgE to
alpha-gal, total IgE levels, and IgE to beef were measured in the studied cases. 22 out of 24 patients had
positive (> 0.35 IU/ml) IgE to beef with variable total
IgE levels. Skin testing was performed on 18 patients
using both commercial and fresh beef extracts, 13 of
which gave positive results. 10 patients had intradermal
testing to beef and all gave positive results. Although
more than 72% of patients had positive SPT to beef and
100% of tested patients had positive intradermal tests to
beef, Commins reported that these reactions were not
impressive when compared to the IgE to beef, and the
severity of reactions they experienced [48]. Studies
showed that fresh extracts of beef and pork contain
more alpha-gal amounts than commercial extracts, and
hence were able to produce better results [18,48]. This
is no surprise as multiple reports showed that the allergenicity of beef changes with the method of processing
and heat exposure [26,89-92]. The source of meat and
the preparation of the extract used in SPT differ
between laboratories and even countries. This indeed
can attribute to the variability of results in each study.
Almost 80% of the studied patients in Commins paper
had no further symptoms of hypersensitivity reactions
after avoidance of red meat. The others had fewer manifestations. Detailed information of the involved patients
and their laboratory results is outlined in Commins and
Platts-Mills original paper [48].
Seven other patients studied in Europe presented with
delayed allergy to red meat, and had IgE levels positive
for alpha-gal and beef [18,52]. In France, investigations
on two patients showed mild SPT reactions to raw beef
and pork, but significant skin reaction when tested with
cetuximab, even with low concentrations [18]. Nunez et
al. in Spain also reported on 5 patients with IgE antibodies specific to alpha-gal, all presenting with severe red
meat allergy. All five patients tested positive for IgE to
beef, pork, lamb, and rabbit. SPT with raw beef and
cetuximab were positive in all five as well [52]. Other
cases with similar history and presentation to alpha-gal
allergy were reported, but to our knowledge testing for
alpha-gal was not conducted [14,53]. Clinical presentations of cases with alpha-gal allergy and variable diagnostic tests are summarized in Additional file 4: Table S4.
A 48-year old male patient with delayed reaction to
beef presented to our clinic in East Tennessee. He
experienced recurrent urticarial eruptions (Figure 5A)
and dyspnea that occurred 5 to 7 hours after red meat
ingestion, including beef and pork. Interestingly, the
patient reported a history of tick bites 2 weeks prior to
his first reaction. Initial blood work showed negative IgE
levels to beef and pork, but repeated testing of the same
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sample was positive to beef. He also had very elevated
levels of IgE specific to alpha-gal. Our patient now
avoids red meat products and has not experienced any
further reactions with food ingestion. Additional laboratory data and information is summarized in Additional
file 4: Table S4 and Figure 5B.
The Presumed Role of Tick Bites

Although genetic factors may predispose an individual
to develop an allergic reaction to beef, Commins provided strong evidence that tick bites likely play an
important role in this development [48,74]. Bites from
the tick species Amblyomma americanum (Lone Star
tick (Figure 2B)), commonly found in the south east and
south central areas of the United States [75], seem to
precede the hypersensitivity to alpha-gal[74]. This phenomenon suggests a role in the sensitization process.
The bite of the lone star tick is associated with the
development of STARI [76] (southern tick-associated rash
illness) usually typified by a large “bulls eye” skin lesion
and accompanied by fever, myalgia, and arthralgia. It is
important to differentiate this illness from lime disease
[76]. How instrumental tick bites are in alpha-gal sensitization, and the mechanism by which this occurs is still
unclear.
In a recent study, Commins and James reviewed three
patients with known IgE levels to alpha-gal, and documented a significant elevation in these levels after exposure to
tick bites [74]. A strong correlation between antibodies to
Amblyomma americanum and those to alpha-gal was present. Additionally, they screened several individuals and
found that most of those whose serum tested positive for
alpha-gal, provided a history of tick bites, irrespective of
whether they had developed meat reactions [74].
In other areas of the world, history of tick bites (different than Amblyomma americanum) is associated with
development of meat-induced allergy [52,53]. In a study
by Van Nunen in Sydney Australia [53], almost all
patients (24/25) presenting with the red meat allergy
gave a history of tick bites. The suspected tick is Ixodes
holocyclus [53], mainly distributed in southeastern Australia [93], and is associated with severe paralysis and cardiovascular problems [94-98]. In Spain 4 of 5 patients
with meat allergy expressed history of tick bites prior to
the reaction [52]. Although no documented proof of the
tick species related to these reactions, the tick common
in that area in Spain (north-western) is Ixodes ricinus
[52]. Cases with reported history of tick bites and the suspected tick are summarized in Additional file 4: Table S4.
Relationship to Dietary Fat and the Presumed Mechanism
of Delay

Another interesting relationship between the areas
where alpha-gal allergy is reported in the United States
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Figure 5 Urticarial eruptions (A) and laboratory data (B) in a patient with alpha-gal related red meat allergy. A 48 year-old patient
presented with recurrent urticarial eruptions and dyspnea 5 to 7 hours after red meat ingestion. Patient reported history of tick bites 2 weeks
prior to his first reaction. Initial workup showed negative IgE to beef and pork. SPT to beef was not performed. Repeated testing was positive to
beef and alpha-gal. Patient avoids red meat products and symptoms are well controlled.

is the obesity rate. The recently reported obesity rates
from the Center of Disease Control and Prevention for
Tennessee, Arkansas, and North Carolina were higher
than those in California and Massachusetts, areas where
alpha-gal allergy is uncommon [51]. This raises the
question of whether high-fat consumption in diet can be
an additional reason for geographical alpha-gal IgE
distribution.
The mechanism behind the delayed presentation of
symptoms after red meat ingestion in patients with IgE
to alpha-gal is still undetermined. A possible explanation
suggested by Commins et al. proposes this delay to the
time needed for red meat to be digested and presented
to circulation [48]. Lipid and glycolipid complexes may
mediate delayed absorption and presentation of alphagal to antigen presenting cells [14,48]. It only takes
about 2 hours for glucose to reach its maximum level in
the plasma after a meal. In contrast, it takes about 4-5
hours for dietary triglycerides to reach their peak in circulation [99,100]. In the postprandial state, dietary triglycerides are packaged in the small intestine into verylow density lipoproteins (VLDLs) and chylomicrons, two
of the largest lipoprotein particles [101]. Due to their
large size, VLDLs (30-80 nm in diameter) and chylomicrons (> 80 nm in diameter) are driven to enter the
lymphatic circulation before being emptied into the
venous circulation via the subclavian vein. Soluble dietary nutrients, such as amino acids and glucose, directly
enter the venous circulation via the superior mesenteric
vein/hepatic portal vein. On the other hand, insoluble
dietary nutrients including long-chain triglycerides,

cholesterol, and lipid-soluble vitamins are packaged by
the small intestine into VLDLs and chylomicrons for
transport through the lymphatic circulation [102].
Alpha-gal is known to be abundantly present on glycolipids and glycoproteins of non-primate mammals,
including the red meat from beef, pork, and lamb [49,50].
Glycolipids and glycoproteins need to be digested in the
intestinal lumen before they can be taken up by enterocytes. These alpha-gal-containing digestion products are
likely lipid soluble and expected to be transported in
VLDLs and/or chylomicrons [48]. The delay of both the
allergic reaction and the peak of dietary triglycerides in
the circulation, suggests that the allergen from red meat
is transported together with dietary triglycerides [48].
Since lipoproteins are made out of a phospholipid monolayer, the alpha-gal containing glycolipids may be
inserted into the phospholipid monolayer with the carbohydrate group facing towards the exterior. The “exposed”
orientation, rather than “buried”, should be optimal for
inducing an allergic reaction. Studies should be aimed
towards determining the presence of alpha-gal in intestinal lipoproteins. The presence of alpha-gal should only
be detected in VLDL/chylomicron fractions from ingestion of red meat from non-primate mammals, and not
from other dietary sources, e.g., chicken and vegetarian
meals.
Food Anaphylaxis and Hypersensitivity Reaction
Management

The delay in appearance of symptoms related to alphagal allergy makes it difficult for patients and physicians
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to identify the trigger [14]. If such an event were to
occur, the patient would be advised to go to the nearest
hospital or emergency room. Once the diagnosis is suspected on the basis of history and epidemiological setting, appropriate testing should be done to confirm the
diagnosis. Following this, preventive measures include
avoidance of red meat and the use of injectable epinephrine [40,48,58,103]. Education and instruction on
use of injectable epinephrine is vital. Acute management
of patients presenting with anaphylaxis, including those
related to alpha-gal, is summarized in Additional file 5:
Table S5.

Conclusion
Alpha-gal allergy is a new and evolving syndrome
related to oligosaccharides, rather than protein, in red
meat. The IgE mediated response to alpha-gal tends to
occur several hours after antigen exposure. This unique
presentation constitutes a challenge to both patients and
physicians, making detailed history very important if
suspected. Reactions to cetuximab seem to be mediated
by an identical mechanism. More studies are required
about this unique syndrome, including an explanation
for the mechanism of delay in presentation and the possible roles obesity and tick bites play in the predisposition for the disorder.
Additional material
Additional file 1: Table 1. Common food allergens.
Additional file 2: Table 2. Meat Allergy Types and Features.
Additional file 3: Table 3. Diagnostic features of alpha-gal-related food
allergy.
Additional file 4: Table 4. Summary of reported cases with alpha-gal
allergy in USA and Europe.
Additional file 5: Table 5. Acute Management and Prevention of
Anaphylaxis*.
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